PreveCeutical Medical Inc. announced that after successfully developing water-based cannabis extract-infused soluble gel formulations (the "CBD Sol-gel Formulations"), the Company has now completed a preliminary safety evaluation (the "Evaluation") of selected CBD Sol-gel Formulations in freshly explanted human nasal mucosal tissue (ex vivo). Over a five-day analysis period during the Evaluation, there was no elevation in "clinically accepted" biomarkers of tissue toxicity. These results would appear to indicate that the selected CBD Sol-gel Formulations that were tested have no acute toxic effects when applied to human nasal mucosal tissue. As medical research into the effects of cannabinoid acids in modulating disease pathways progresses, it is expected that benefits of cannabinoid acids will emerge, and the Company will be well-positioned with its CBD Sol-gel Formulations. The CBD Sol-gel Formulations, when used with the Company's customized soluble gel ("Sol-gel") applicator device for direct nose-to-brain delivery (the "Sol-gel Applicator"), is expected to target direct and prolonged delivery of cannabinoids to a patients' central nervous system. Future repetitive evaluations are required of the Company's sol-gel drug delivery research and development program (the "Sol-gel Program"), which may involve pre-clinical/clinical evaluation of the CBD Sol-gel Formulation.